Open AccessLongitudinal multimodal imaging-compatible mouse model of triazole-sensitive and -resistant invasive pulmonary aspergillosis
Author(s) -
Agustin Reséndiz-Sharpe,
Roberta Peres da Silva,
Elena Geib,
Lore Vanderbeke,
Laura Seldeslachts,
Charlien Hupko,
Matthias Brock,
Katrien Lagrou,
Greetje Vande Velde
Publication year - 2022
Publication title -
disease models and mechanisms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.327
H-Index - 83
eISSN - 1754-8411
pISSN - 1754-8403
DOI - 10.1242/dmm.049165
Subject(s) - aspergillus fumigatus , aspergillosis , bioluminescence imaging , in vivo , neutropenia , antifungal , biology , voriconazole , triazole , immunosuppression , bioluminescence , microbiology and biotechnology , immunology , chemotherapy , chemistry , cell culture , biochemistry , luciferase , transfection , genetics , organic chemistry
Invasive pulmonary aspergillosis (IPA) caused by the mold Aspergillus fumigatus is one of the most important life-threatening infections in immunocompromised patients. The alarming increase of isolates resistant to the first-line recommended antifungal therapy urges more insights into triazole-resistant A. fumigatus infections. In this study, we systematically optimized a longitudinal multimodal imaging-compatible neutropenic mouse model of IPA. Reproducible rates of pulmonary infection were achieved through immunosuppression (sustained neutropenia) with 150 mg/kg cyclophosphamide at day −4, −1 and 2, and an orotracheal inoculation route in both sexes. Furthermore, increased sensitivity of in vivo bioluminescence imaging for fungal burden detection, as early as the day after infection, was achieved by optimizing luciferin dosing and through engineering isogenic red-shifted bioluminescent A. fumigatus strains, one wild type and two triazole-resistant mutants. We successfully tested appropriate and inappropriate antifungal treatment scenarios in vivo with our optimized multimodal imaging strategy, according to the in vitro susceptibility of our luminescent fungal strains. Therefore, we provide novel essential mouse models with sensitive imaging tools for investigating IPA development and therapy in triazole-susceptible and triazole-resistant scenarios.